September 01, 2017
Gilead Sciences to Present at Citi’s 12th Annual Biotech Conference on Wednesday, September 6
Webcast Available Through Gilead Corporate Website
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 1, 2017--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kevin Young
CBE, Gilead’s Chief Operating Officer, Norbert W. Bischofberger, PhD,
Gilead’s Executive Vice President, R&D and Chief Scientific Officer, and
Robin L. Washington, Gilead’s Executive Vice President and Chief
Financial Officer, will participate in a fireside chat at Citi’s 12th
Annual Biotech Conference in Boston on Wednesday, September 6 at 11:00
a.m. Eastern Time.
The audio portion of the fireside chat will be accessible live through
the company’s Investors page at www.gilead.com/investors.
Please connect to the company’s website at least 15 minutes prior to the
start of the presentation to ensure adequate time for any software
download that may be required to listen to the webcast. The replay will
be available for 14 days following the presentation.
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170901005101/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.
Sung Lee, 650-524-7792